Clinical Trial Update: Donafenib Plus Sintilimab for Advanced HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating donafenib in combination with sintilimab for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED